Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanabenz. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanabenz SCHEMBL21519525 | 1.00 | CYP1A2 (0.58) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL11756795 | 1.00 | CYP1A2 (0.58) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL40594 | 1.00 | CYP1A2 (0.58) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL5918283 | 1.00 | CYP1A2 (0.58) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL22616227 | 0.99 | CYP1A2 (0.57) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL22616226 | 0.99 | CYP1A2 (0.57) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL3714055 | 0.95 | CYP1A2 (0.53) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL21519450 | 0.94 | KMT2A (0.52) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Acetic Acid SCHEMBL21519627 | 0.92 | KDM1A (0.52) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Acetic Acid SCHEMBL21519637 | 0.92 | NPSR1 (0.56) | CYP1A2NPSR1LMNACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5272165-A | 2-alkylidene-aminoguanidines and methods of use therefor | THE ROCKEFELLER UNIVERSITY (US) | 1993-12-21 | — | — | US | claimed |
| WO-1992019236-A1 | 2-ALKYLIDENE-AMINOGUANIDINES FOR INHIBITING ADVANCED NONENZYMATICGLYCOSYLATION OF PROTEINS | THE ROCKEFELLER UNIVERSITY (US) | 1992-11-12 | — | — | WO | claimed |
| US-5130324-A | For inhibiting nonezymatic crosslinking of glycosylation products of proteins | THE ROCKEFELLER UNIVERSITY (US) | 1992-07-14 | — | — | US | claimed |
| US-20240293343-A1 | Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications | INFLECTIS BIOSCIENCE (FR) | 2024-09-05 | — | — | US | disclosed |
| US-12006294-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-06-11 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| WO-1992019236-A1 | 2-ALKYLIDENE-AMINOGUANIDINES FOR INHIBITING ADVANCED NONENZYMATICGLYCOSYLATION OF PROTEINS | THE ROCKEFELLER UNIVERSITY (US) | 1992-11-12 | — | — | WO | disclosed |
| US-5130324-A | For inhibiting nonezymatic crosslinking of glycosylation products of proteins | THE ROCKEFELLER UNIVERSITY (US) | 1992-07-14 | — | — | US | disclosed |
| US-4032659-A | ADMINISTERING THIOSEMICARBAZONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
| US-4027039-A | ADMINISTERING AMINOGUANIDINE, GUANIDINE, OR 1-(SEC-BUTYLIDENEAMINO)GUANIDINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
| US-3980774-A | HYDRAZINE AND HYDRAZINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | ADRA2A 296/4885ADRA2B 328/4885ADRA2C 377/4885 |
| US-20240293343-A1 | Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications | GRIN2B, GRIN2A, GRIN3A | ADRA2A 197/4885ADRA2B 176/4885ADRA2C 330/4885 |
| US-12006294-B2 | Therapeutic compounds | OPRL1, INA, OGFR | ADRA2A 296/4885ADRA2B 328/4885ADRA2C 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.